Terms: = Prostate cancer AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734
81336 results:
1. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
2. Antiproliferative and Apoptotic Effects of Murici (Byrsonima crassifolia (L.) Kunth and verbascifolia (L.) DC) and Taperebá (Spondias mombin L.) Extracts in Human prostate Cell Line (PC-3).
Amaral Muxfeldt Paim TOD; Simas NF; Abreu JP; Rosa L; Passos Barbosa Lima T; Teodoro AJ
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1339-1347. PubMed ID: 38679995
[TBL] [Abstract] [Full Text] [Related]
3. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
[TBL] [Abstract] [Full Text] [Related]
4. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
5. Effects of Red Sorghum-Derived Deoxyanthocyanidins and Their O-β-D-Glucosides on E-Cadherin Promoter Activity in PC-3 prostate cancer Cells.
Mora N; Rosa M; Touaibia M; Martin LJ
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675711
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
7. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
8. A Community-Based prostate cancer Screening and Education Program for Asian American Men in Medically Underserved Communities.
Cho D; Gor B; Hwang H; Wang X; Hernandez M; Jones LA; Frost J; Roberson P; Pettaway CA
Int J Environ Res Public Health; 2024 Mar; 21(4):. PubMed ID: 38673327
[TBL] [Abstract] [Full Text] [Related]
9. Synthesis and Validation of TRIFAPYs as a Family of Transfection Agents for Therapeutic Oligonucleotides.
Isanta B; Delgado A; Ciudad CJ; Busquets MA; Griera R; Llor N; Noé V
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672408
[TBL] [Abstract] [Full Text] [Related]
10. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
Veras ASC; Batista VRG; Correia RR; de Almeida Tavares ME; Rubira RJG; Tavares ER; Giometti IC; Maranhão RC; Teixeira GR
Sci Rep; 2024 Apr; 14(1):9626. PubMed ID: 38671015
[TBL] [Abstract] [Full Text] [Related]
11. Breakthrough electroneutron multi-response miniature dosimetry/spectrometry in medical accelerator.
Sohrabi M; Malekitakbolagh M; Nedaei HA
Sci Rep; 2024 Apr; 14(1):9557. PubMed ID: 38664481
[TBL] [Abstract] [Full Text] [Related]
12. Cotrimoxazole and targeted antibiotic prophylaxis for transrectal prostate biopsy: a single-center study.
Jahnen M; Amiel T; Kirchoff F; Büchler JW; Herkommer K; Rothe K; Meissner VH; Gschwend JE; Lunger L
World J Urol; 2024 Apr; 42(1):260. PubMed ID: 38664275
[TBL] [Abstract] [Full Text] [Related]
13. Genomic Correlates of prostate-Specific Membrane Antigen Expression and Response to
Raychaudhuri R; Mo G; Tuchayi AM; Graham L; Gulati R; Pritchard CC; Haffner MC; Yezefski T; Hawley JE; Cheng HH; Yu EY; Grivas P; Montgomery RB; Nelson PS; Chen DL; Hope T; Iravani A; Schweizer MT
JCO Precis Oncol; 2024 Apr; 8():e2300634. PubMed ID: 38662984
[TBL] [Abstract] [Full Text] [Related]
14. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
15. AZGP1 deficiency promotes angiogenesis in prostate cancer.
Wen RM; Qiu Z; Marti GEW; Peterson EE; Marques FJG; Bermudez A; Wei Y; Nolley R; Lam N; Polasko AL; Chiu CL; Zhang D; Cho S; Karageorgos GM; McDonough E; Chadwick C; Ginty F; Jung KJ; Machiraju R; Mallick P; Crowley L; Pollack JR; Zhao H; Pitteri SJ; Brooks JD
J Transl Med; 2024 Apr; 22(1):383. PubMed ID: 38659028
[TBL] [Abstract] [Full Text] [Related]
16. Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer.
Ying Y; Wu Y; Zhang F; Tang Y; Yi J; Ma X; Li J; Chen D; Wang X; Liu X; Liu B; Luo J; Zheng X; Xie L
Mol Cancer; 2024 Apr; 23(1):79. PubMed ID: 38658974
[TBL] [Abstract] [Full Text] [Related]
17. [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer].
Wikström P; Bergh A; Josefsson A; Thysell E; Welén K
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38656744
[TBL] [Abstract] [Full Text] [Related]
18. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
[TBL] [Abstract] [Full Text] [Related]
19. The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids.
Lachance G; Robitaille K; Laaraj J; Gevariya N; Varin TV; Feldiorean A; Gaignier F; Julien IB; Xu HW; Hallal T; Pelletier JF; Bouslama S; Boufaied N; Derome N; Bergeron A; Ellis L; Piccirillo CA; Raymond F; Fradet Y; Labbé DP; Marette A; Fradet V
Nat Commun; 2024 Apr; 15(1):3431. PubMed ID: 38654015
[TBL] [Abstract] [Full Text] [Related]
20. Developing a Novel Enzalutamide-Resistant prostate cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract] [Full Text] [Related]
[Next]
